Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia

Ibrutinib has emerged as a promising therapy for patients with chronic lymphocytic leukemia (CLL) who are nonresponsive to standard therapies. The refractory state of monocytes and T-cell exhaustion in patients with CLL could explain the morbidity and mortality reported in these patients. We studied...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Cubillos-Zapata, Carolina, Avendaño-Ortiz, Jose, Córdoba, Raúl, Hernández-Jiménez, Enrique, Toledano, Victor, Pérez de Diego, Rebeca, López-Collazo, Eduardo
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5213769/
https://ncbi.nlm.nih.gov/pubmed/28123879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1242544
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky